

1994) using the 1.64 Å CypA structure of Ke et al. (1993) (PDB code 2CYH) as the search model. The top solution for two CypA molecules gave a correlation coefficient of 0.43 and an R value of 45% against 7.0–3.5 Å data.

In order to build the CA₁₅₁ structure, structure factors were calculated from the rigid body–refined CypA structure, weights were calculated with SIGMAA (Read, 1986), and phases were refined by solvent flattening and histogram shifting with dm (Cowtan, 1994). Inspection of the density allowed assignment of noncrystallographic symmetry (NCS) operators for the CA₁₅₁ molecules and further phase refinement by 2-fold averaging. The resulting unbiased electron density map for CA₁₅₁ was readily interpretable (Figure 7).

Rounds of refinement with X-PLOR (Brunger, 1992) were interspersed with model building using O (Jones et al., 1991). Prior to the start of atomic refinement, 10% of the data were assigned to the free R set to allow cross validation. During refinement, NCS restraints were applied to 124 residues of CypA and 70 residues of CA₁₅₁. NCS restraints were also applied to backbone atoms (N, C^α, C', O, and C^β) for an additional 8 and 18 residues of CypA and CA₁₅₁, respectively. Refinement cycles were only accepted if they gave a lower free R value. The free R value was also used to select the relative weights for X-ray and stereochemical terms and the resolution range used in refinement. All data between 6.0 and 2.36 Å were used in the refinement. The current R value is 23.8% (free R value: 30.6%). In the highest resolution shell (2.46–2.36 Å), the R value is 35.0% (free R value: 40.2%). The stereochemistry is good; RMSD (bonds) = 0.005 Å; RMSD (angles) = 1.3°; there are no ϕ, ψ angles in the forbidden range (Laskowski et al., 1993). A total of 107 water molecules have been located with average thermal factors (25.2 Å²) that are almost identical to those of the protein (25.0 Å²). Water molecules were included conservatively and were evaluated carefully with regard to appearance of the electron density, contacts with protein, and changes in the free R value. Special care was taken with CA₁₅₁ Pro-90 because the equivalent proline is *cis* in all previously reported CypA–peptide complexes. Refinement calculations and electron density clearly indicate the *trans* conformation.

Regions that lack well-defined density have been given an occupancy of zero for crystallographic refinement and for R value calculations. Residues with zero occupancy are: CypA-1; 80, 81, and 165, CypA-2; 80 and 81, CA₁₅₁-1; 6–8, CA₁₅₁-2; and 1–11, 31, 60–63, and 95–96. The following residues were given zero occupancy beyond their C^β atoms: CypA-1; 15, 91, and 144, CypA-2; 1, 15, 69, 144, and 151, CA₁₅₁-1; 4, 18, 25, 30, 35, 63, 95, 112, 121, and 128, CA₁₅₁-2; and 18, 21, 28–30, 35, 45, 50, 67, 70–71, 112, 128, and 140. The following residues were completely omitted from the model: CypA-1; 1–2, 165; CA₁₅₁-1; 146–151; and CA₁₅₁-2; 146–151.

The N-terminal hairpin of CA₁₅₁ is well defined for CA₁₅₁-1, except for residues 6–8. However, in CA₁₅₁-2, none of the residues preceding His-12 have well-defined density. Some density was evident for residues 1–3 and 10–11, although model building into this density relied heavily on the conformation seen in CA₁₅₁-1.

Acknowledgments

We thank Steven C. Johnston, Robert E. Sweet, and Malcolm Capel for assistance with data collection; Christine A. Settineri for mass spectrometry; Sherwood Casjens, Venki Ramakrishnan, and members of our laboratories for critical reading of the manuscript; Hengming Ke for coordinates of CypA/succinyl-Ala-Ala-Pro-Phe-pNA, and Jeremy Luban for preprints. This work was supported by grants from the NIH (W. I. S. and C. P. H.), the Lucille P. Markey Charitable Trust, and a postdoctoral fellowship from the Cancer Research Institute (T. R. G.).

Correspondence and requests for materials should be addressed to W. I. S. (sundquist@medschool.med.utah.edu) or C. P. H. (chris@msscc.med.utah.edu). Coordinates and diffraction data will be deposited with the Brookhaven Protein Database.

Received September 3, 1996; revised November 11, 1996.

References

Aberham, C., Weber, S., and Phares, W. (1996). Spontaneous mutations in the human immunodeficiency virus type 1 *gag* gene that

affect viral replication in the presence of cyclosporins. *J. Virol.* **70**, 3536–3544.

Anderson, S.K., Gallinger, S., Roder, J., Frey, J., Young, H.A., and Ortaldo, J.R. (1993). A cyclophilin-related protein involved in the function of natural killer cells. *Proc. Natl. Acad. Sci. USA* **90**, 542–546.

Bacon, D.J., and Anderson, W.F. (1988). A fast algorithm for rendering space-filling molecule pictures. *J. Molec. Graphics* **6**, 219–220.

Baker, E.K., Colley, N.J., and Zuker, C.S. (1994). The cyclophilin homolog NinaA functions as a chaperone, forming a stable complex in vivo with its protein target rhodopsin. *EMBO J.* **13**, 4886–4895.

Billich, A., Hammerschmid, F., Peichl, P., Wenger, R., Zenke, G., Quesniaux, V., and Rosenwirth, B. (1995). Mode of action of SDZ NIM 811, a nonimmunosuppressive cyclosporin A analog with activity against human immunodeficiency virus (HIV) type 1: Interference with HIV protein-cyclophilin A interactions. *J. Virol.* **69**, 2451–2461.

Braaten, D., Aberham, C., Franke, E.K., Yin, L., Phares, W., and Luban, J. (1996a). Cyclosporine A-resistant human immunodeficiency virus type 1 mutants demonstrate that *gag* encodes the functional target of cyclophilin A. *J. Virol.* **70**, 5170–5176.

Braaten, D., Franke, E.K., and Luban, J. (1996b). Cyclophilin A is required for an early step in the life cycle of human immunodeficiency virus type 1 before the initiation of reverse transcription. *J. Virol.* **70**, 3551–3560.

Braaten, D., Franke, E.K., and Luban, J. (1996c). Cyclophilin A is required for the replication of group M human immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus SIV_{cpz}GAB but not group O HIV-1 or other primate immunodeficiency viruses. *J. Virol.* **70**, 4220–4227.

Bram, R.J., and Crabtree, G.R. (1994). Calcium signalling in T cells stimulated by a cyclophilin B-binding protein. *Nature* **371**, 355–358.

Brunger, A.T. (1992). X-PLOR, a system for X-ray crystallography and NMR. Vol. Version 3.1, Yale University. (New Haven, Connecticut: Yale University Press).

Colgan, J., Yuan, H.E.H., Franke, E.K., and Luban, J. (1996). Binding of the human immunodeficiency virus type 1 *gag* polyprotein to cyclophilin A is mediated by the central region of capsid and requires *gag* dimerization. *J. Virol.* **70**, 4299–4310.

Colley, N.J., Baker, E.K., Stamnes, M.A., and Zuker, C.S. (1991). The cyclophilin homolog NinaA is required in the secretory pathway. *Cell* **67**, 255–263.

Cowtan, K.D. (1994). 'dm': an automated procedure for phase improvement by density modification. *Joint CCP4 and ESF-EACMB newsletter on protein crystallography* **37**, 34–38.

Dorfman, T., Bukovsky, A., Öhagen, Å., Höglund, S., and Göttlinger, H.G. (1994). Functional domains of the capsid protein human immunodeficiency virus type 1. *J. Virol.* **68**, 8180–8187.

Dorfman, T., Luban, J., Goff, S.P., Haseltine, W.A., and Göttlinger, H.G. (1993). Mapping of functionally important residues of a cysteine-histidine box in the human immunodeficiency virus type 1 nucleocapsid protein. *J. Virol.* **67**, 6159–6169.

Ferrin, T.E., Huang, C.C., Jarvis, L.E., and Langridge, R. (1988). The MIDAS display system. *J. Mol. Graphics* **6**, 13–27.

Franke, E.K., Yuan, H.E.H., Bossolt, K.L., Goff, S.P., and Luban, J. (1994a). Specificity and sequence requirements for interactions between various retroviral *gag* proteins. *J. Virol.* **68**, 5300–5305.

Franke, E.K., Yuan, H.E.H., and Luban, J. (1994b). Specific incorporation of cyclophilin A into HIV-1 virions. *Nature* **372**, 359–362.

Gelderblom, H.R., Bauer, P.G., Özel, M., Höglund, S., Niedrig, M., Renz, H., Morath, B., Lundquist, P., Nilsson, Å., Mattow, J., et al. (1992). Morphogenesis and morphology of human immunodeficiency virus. In *Membrane Interactions of HIV*, R.C. Aloia, and C.C. Curtain, eds. (New York: Wiley-Liss, Inc.), pp. 33–54.

Gitti, R.K., Lee, B.M., Walker, J., Summers, M.F., Yoo, S., and Sundquist, W.I. (1996). Structure of the amino-terminal core domain of the HIV-1 capsid protein. *Science* **273**, 231–235.

Harrison, R.K., and Stein, R.L. (1990a). Mechanistic studies of peptidyl prolyl *cis-trans* isomerase: evidence for catalysis by distortion. *Biochemistry* **29**, 1684–1689.